Low-dose CT has become a mainstay for PET attenuation correction, but why not take it a step further by quantifying coronary artery calcium without adding any extra dose, according to an Ottawa Heart Institute study published ahead of print Nov. 20 in the Journal of Nuclear Cardiology.

During my term as president of the Society of Nuclear Medicine (And Molecular Imaging, now appended), we were in the midst of the Molecular Imaging Campaign that was successful in increasing the visibility of nuclear medicine as a measure of physiologic and metabolic parameters in diagnosing our patients.

A year-to-date sales report for the radiopharmaceutical company Advanced Accelerator Applications (AAA) indicates that the company experienced 28.9 percent growth in sales, equaling about $68.7 million in the first nine months of 2014. Net income for the first three quarters of the year was gauged at approximately $1.5 million.

Targeting oncogene-driven activation of DNA damage could be an effective way to tap into the earliest stages of cancer development, or tumorigenesis. An investigative molecular imaging agent was able to do just that in a preclinical Oxford University study published ahead of print Nov. 13 in the Journal of Nuclear Medicine.

Navidea Biopharmaceuticals announced today that technetium-99m tilmanocept (Lymphoseek) has been approved by the European Commission for the detection of sentinel lymph node involvement in primary breast cancer, melanoma and localized squamous cell carcinoma.

When four-state Mercy broke ground on a four-story, 120,000-square-foot virtual-care center on a patch of green in Chesterfield, Mo., last spring, the blueprint represented a bold and visionary step into American healthcare’s digital future, as the center may be the first of its kind anywhere in the world. The organization estimates that the center will manage more than three million telehealth visits in the first five years following its scheduled 2015 opening.

Protea Biosciences, a biomedical company based in Morgantown, W. Va, announced yesterday that third quarter financial results amounted to $517,569, the highest revenue on record for the company. However net losses are still steep at more than $4.6 million for the third quarter.

Even mild cases of dental disease could have long-term effects on amyloid plaque development and brain health, according to a neuroimaging study published online Nov. 5 in Neurobiology of Aging.